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Abstract: 
Chronic hypertension in pregnancy is associated with significant adverse pregnancy 
outcomes, increasing the risk of pre-eclampsia, fetal growth restriction and preterm birth. 
Dietary nitrate, abundant in green leafy vegetables and beetroot, is reduced in vivo to nitrite 
and subsequently nitric oxide, and has been demonstrated to lower blood pressure, improve 
vascular compliance and enhance blood flow in non-pregnant humans and animals.  
The primary aims of this study were to determine the acceptability and efficacy of dietary 
nitrate supplementation, in the form of beetroot juice, to lower blood pressure in hypertensive 
pregnant women. In this double-blind, placebo-controlled feasibility trial, 40 pregnant 
women received either daily nitrate supplementation (70mL beetroot juice, n=20) or placebo 
(70mL nitrate-depleted beetroot juice, n=20) for 8 days. Blood pressure, cardiovascular 
function and uteroplacental blood flow was assessed at baseline and following acute (3 hours) 
and prolonged (8 days) supplementation. Plasma and salivary samples were collected for 
analysis of nitrate and nitrite concentrations and acceptability of this dietary intervention was 
assessed based on questionnaire feedback. Dietary nitrate significantly increased plasma and 
salivary nitrate/nitrite concentrations compared with placebo juice (p<0.001), with marked 
variation between women. Compared with placebo, there was no overall reduction in blood 
pressure in the nitrate-treated group; however there was a highly significant correlation 
between changes in plasma nitrite concentrations and changes in diastolic blood pressure in 
the nitrate-treated arm only (r=-0.6481; p=0.0042). Beetroot juice supplementation was an 
acceptable dietary intervention to 97% of women. This trial confirms acceptability and 
potential efficacy of dietary nitrate supplementation in pregnant women. Conversion of 
nitrate to nitrite critically involves oral bacterial nitrate reductase activities. We speculate that 
differences in efficacy of nitrate supplementation relate to differences in the oral microbiome, 
which will be investigated in future studies.   
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1. Introduction: 
Chronic hypertension in pregnancy affects up to 3% of all pregnancies [1] and is defined by 
blood pressure (BP) greater than 140mmHg systolic (SBP) and/or 90mmHg diastolic (DBP) 
on two separate occasions before 20 weeks’ gestation/beyond 12 weeks postpartum [2; 3]. 
Pregnancies complicated by chronic hypertension are increasingly prevalent, likely secondary 
to increasing maternal age [4], obesity [5] and metabolic syndrome [6]. Women with chronic 
hypertension are less likely to undergo successful cardiovascular adaptations in mid-
pregnancy, including the normal reduction in BP and peripheral vascular resistance, which 
play a vital role in fetoplacental development. Consequently, these women are at increased 
risk of complications including fetal growth restriction (FGR; [7], placental abruption [8], 
indicated preterm birth [9] and pre-eclampsia (PE; 8-fold increase; [10; 11]). Despite the 
prevalence of adverse outcomes in this group of women and their association with level of 
hypertension [12], treatment options for hypertension in pregnancy are limited, making the 
development of new antihypertensive agents suitable for use in pregnancy a key research 
priority [2].  
 
The development and use of pharmacological interventions in pregnancy is often hindered by 
a paucity of safety data and anxiety from women and clinicians alike of causing harm to the 
fetus. In recent years, there have been concerns that antihypertensive treatments might reduce 
uteroplacental perfusion, thereby negatively impacting on fetal growth. This was not 
demonstrated in the CHIPS trial, however [13], which was an unblinded multi-centre 
randomised controlled trial investigating the consequences of less-tight (DBP≤100mmHg) 
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versus tight (DBP≤95mmHg) BP control, using standard antihypertensive medications, in 
pregnancy. It contrasted previous smaller studies [14] in demonstrating no significant 
difference in adverse perinatal outcomes between the two groups. Instead, there was a 
significantly increased risk of severe hypertension in women whose blood pressure was under 
less-tight control [13]. There is ongoing debate regarding blood pressure targets in women 
with non-severe hypertension (SBP 130-144mmHg, DBP 80-94mmHg), and this group of 
women remain under-researched in intervention trials. As the CHIPS trial data highlights, it 
may be important to control blood pressure in borderline hypertensive pregnant women in 
order to prevent severe hypertension and subsequent poor pregnancy outcomes.  
 
Nitric oxide (NO) is a potent vasodilator, crucial in maintaining a low resistance 
cardiovascular system and key in mediating maternal cardiovascular adaptations of 
pregnancy. In both humans and animals, NO levels are reported to increase across pregnancy 
[15; 16; 17; 18; 19] and, in some reports, reductions in NO production have been associated 
with pregnancy pathologies, including FGR and PE [15; 16; 17]. Several therapies aiming to 
enhance NO bioavailability are currently in obstetric trials [20]. Dietary nitrate (abundant in 
green leafy vegetables and beetroot) provides an alternative source of nitric oxide (NO), and 
in recent years the therapeutic potential for nitrate supplementation has been demonstrated in 
a number of clinical [21; 22; 23; 24] and preclinical [23; 25; 26] studies. Dietary nitrate is 
absorbed and subsequently reduced to nitrite by commensal bacteria via the entero-salivary 
pathway. Nitrite then enters the systemic circulation, and can be reduced to NO in the blood 
or in tissues [27]. The current trial draws on recent evidence demonstrating that dietary 
nitrate supplementation significantly lowers BP in both normotensive [24] and hypertensive 
[23] subjects out-with pregnancy. A single dose of beetroot juice, which is a rich source of 
nitrate, was sufficient to reduce BP, an effect that peaked at ~3 hours post-ingestion and 
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persisted for at least 24 hours [23]. Beetroot juice has also been shown to increase blood flow 
and reduce vascular resistance in non-pregnant animal models [25]. More recently, 
preliminary data from our laboratory in a mouse model of hypertension in pregnancy has 
shown that 6 days of supplementation with beetroot juice can reduce BP and improve 
maternal uterine artery endothelial function [Cottrell et al., unpublished]. In addition to these 
promising effects on blood pressure regulation and vascular function, it is likely that a dietary 
intervention such as beetroot juice might be more acceptable to pregnant women than anti-
hypertensive medications.  Thus, this feasibility study aimed to determine the acceptability 
and efficacy of dietary nitrate supplementation, from beetroot juice, as an intervention to 
reduce blood pressure in pregnant women with borderline hypertension. 
 
2. Subjects and Methods 
 
2.1 Trial design 
This study was a single-site, double-blind, randomised controlled trial (RCT) and was 
prospectively registered at clinicaltrials.gov (study identifier: NCT02520687). Study protocol 
and documentation were granted full ethical approval by the local research ethics committee 
(REC reference 15/NW/0383; full protocol available on request). Participants were recruited 
after being identified and approached through the Maternal and Fetal Health Research Centre 
(MFHRC) high-risk antenatal clinics. All participants provided informed consent. 
Participants were recruited between October 2015 and February 2017; the final participant 
delivered in April 2017. All data were collected during study appointments at the MFHRC 
(St Mary’s Hospital, Manchester, UK) by specialist research midwives and obstetricians. The 
intervention (a total of 8 days of beetroot juice supplementation) was completed between 
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22+0 and 35+6 weeks’ gestation. Pregnancy outcome data was collected for all women 
following delivery. 
 
2.2 Eligibility criteria 
Women with a diagnosis of borderline chronic hypertension (SBP 130-144mmHg and/or 
DBP 80-94mmHg before 20 weeks’ gestation), who were not taking anti-hypertensive 
medication, and who were between 22 and 35+6 weeks of gestation were included in the 
study. Exclusion criteria were: pre-existing diabetes (type I or II), multiple pregnancy, 
concomitant antihypertensive medication, age under 16 and incapacity to provide informed 
consent. 
 
2.3 Intervention 
Participants were given 70mL treatment/placebo juice daily (James White Drinks Ltd), for a 
total of 8 days. The treatment juice contained ~400mg nitrate in 70 mL of beetroot juice (92.4 
± 11.9 mmol/L); placebo treatment was 70mL of a nitrate-depleted beetroot juice (containing 
<0.01 mmol/L nitrate; James White Drinks Ltd), identical otherwise in taste and appearance 
[28]. Women were advised to continue their normal diet during the study, and were asked to 
take the allocated treatment at approximately the same time each day. In all women, blood 
samples and blood pressure/cardiovascular parameters were determined at baseline (0 hours), 
3 hours and 24 hours after the first dose of treatment, and then on day 8, prior to the final 
treatment dose (see detailed description below and Supplementary Figure 1 for overview of 
study design). 
 
2.4 Randomisation method and blinding 
Block randomisation was performed in advance (using an online programme; block size of 4, 
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1:1 allocation) and sequentially numbered prefilled treatment envelopes (containing the week 
of supplementation) were created by a researcher independent of the study team 
consenting/administering and performing measurements (MW). Thus, both the participant 
and the member of the research team assessing the clinical outcomes were blinded to the 
treatment arm. 
 
2.5 BP measurements 
BP and heart rate (HR) were measured in each arm in the sitting position (once in each arm, 
data averaged to obtain mean sitting BP) and 4 repeated BP measurements were taken in the 
lying position in the left arm during the ultrasound scan (using Alere Microlife BP monitors; 
Cheshire, UK). The Arteriograph® (Tensiomed, Budapest, Hungary) was used to measure 
HR, SBP, DBP and to calculate pulse wave velocity (PWV) and augmentation index (both 
measures of arterial stiffness) in both left lateral (LL) and supine positions; this was recorded 
via the manufacturer’s software. Non-invasive cardiac output monitoring (NICOM) system 
(Cheetah Medical (UK) Ltd, Maidenhead, UK) was used to measure HR, SBP, DBP and 
peripheral vascular resistance. Uteroplacental Doppler measurements (uterine artery, 
umbilical artery/vein) were performed in triplicate (Voluson E6, GE Healthcare; 
measurements made using a 4-8mHz curvilinear transabdominal probe). Ambulatory blood 
pressure measurement (24-hour ABPM) was performed using validated machines (Model 
90207, Spacelabs Healthcare Ltd, Hertfordshire, UK) on day one and day 8 of the treatment 
period.  Between 0700-2300h, one reading every 30 minutes was taken; from 2300-0700, one 
reading every hour was taken. At each visit, measurements were taken in the same order for 
each participant; salivary and blood sampling was completed after cardiovascular/Doppler 
measurements and prior to treatment ingestion. 
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2.6 Outcomes 
The primary process outcome for this study was recruitment rate (calculated as number 
recruited/total number of eligible women contacted). The secondary process outcome was the 
acceptability of the intervention, based on feedback from a questionnaire (see Supplementary 
Data). The primary clinical outcome was to identify a reduction in clinic BP (using sitting 
position BP values) in the treatment group, compared with placebo. Secondary clinical 
outcomes were to determine (1) average day and night time ABPM measurements (measured 
on day 1 and day 8); (2) pulse-wave velocity (PWV); (3) total peripheral vascular resistance 
(TPRI); (4) uteroplacental blood flow parameters (uterine and umbilical artery resistance (RI) 
and pulsatility indices (PI)); and (5) changes in salivary and plasma nitrate/nitrite 
concentrations in response to treatment. We also aimed a priori to determine whether BP or 
other cardiovascular variables correlated with changes in plasma nitrite concentrations, as 
seen in previous studies [22]. 
 
2.7 Biochemical measurements 
Venous blood samples were collected at 0, 3, 24 hour and day 8 timepoints into collection 
tubes (BD 364938) and EDTA added to a final concentration of 2mM. Blood was centrifuged 
immediately and plasma removed and stored at -80°C until analysis.  Saliva was collected in 
parallel at these same timepoints, directly into 1.5mL Eppendorf tubes, frozen immediately 
and stored at -80°C until analysis. Plasma and salivary content of nitrate and nitrite was 
measured using a high-performance liquid chromatography (HPLC) system (ENO-20; 
Eicom) as previously described [26]. 
 
 
 
9 
 
2.8 Sample size calculation 
Whilst primarily a feasibility study, this study was powered to detect a reduction in BP of 
5mmHg with 80% power and a 95% level of confidence. This is a conservative yet clinically 
relevant change, which is in line with previous studies investigating beetroot juice 
administration in non-pregnant subjects [22; 24]. Assuming a standard deviation of 6.2 
mmHg in BP measurements in pregnancy (based on studies measuring BP by the same means 
as this trial [29]), and using a one-sided t-test, the target sample size was 40 completing 
participants (1:1 allocation). The block randomisation list included 44 participants to allow 
for non-completion.  
 
2.9 Statistical analysis 
Variables were checked for normality using the Jarque-Bera skewness-kurtosis test and 
outliers identified using the ROUT method (with Q=0.1% for removal of definitive outliers). 
Reproducibility of repeated measurements and agreement between BP/HR measurements 
using different modalities were assessed using intraclass correlation coefficients (ICC) and 
Bland Altman analyses, respectively. Comparisons between devices were made using lyin 
(supine) position measurements only, to account for postural effects on BP. The primary 
outcome (blood pressure change) was compared using t-test, between time 0 and 3hr, 24hr 
and day 8 (168 hour) time points. The remaining outcomes were compared using Mann-
Whitney and ANOVA as appropriate; p<0.01 was considered significant (to account for 
multiple comparisons). Associations between biochemical and BP measurements were 
assessed using Pearson’s linear correlation, with p<0.01 considered significant. All statistical 
analyses were performed using Stata/IC (version 14.1, StataCorp, Texas, USA) or GraphPad 
Prism (version 7.00, GraphPad Software, La Jolla California USA). 
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3. Results 
Study population characteristics and pregnancy outcome data are summarised in Table 1.  
Out of the 58 eligible women approached, 44 women agreed to participate, and a total of 40 
women (40/58; 69%) completed the study (Figure 1). For all 14 women who declined to 
participate, time commitment was cited as the primary reason. Of the 44 recruited women, 2 
withdrew (1 on the first visit and the other prior to the final visit) and 2 were excluded due to 
the development of pregnancy complications during the trial period. The participant who 
withdrew before the final visit was included in baseline, 3 and 24 hour analyses (Figure 1). 
 Nitrate (n=20) Placebo (n=21) All 
Gestation (weeks + days) 
Median (range) 
28+1 
(22+5 –  35+5) 
27+1 
(22+5 – 34+6) 
 
Ethnicity; N (%)    
White 13 (65.00%) 14 (66.67%) 27 (65.85%) 
Black 5 (25.00%) 7 (33.33%) 12 (29.27%) 
Asian 1 (5.00%) 0 1 (2.44%) 
Other 1 (5.00%) 0 1 (2.44%) 
BMI (kg/cm
2
) 
Median (range), [IQR] 
34.01 
(19.87 – 49.61) 
[11.64] 
26.99 
(19.29 – 40.03) 
[9.46] 
29.97 
(19.29 – 49.61) 
[11.20] 
Booking SBP (mmHg) 
Median (range) 
135 
(110 – 171) 
129 
(110 – 166) 
130 
(110 – 171) 
Booking DBP (mmHg) 
Median (range) 
81 
(64 – 100) 
80 
(60 – 90) 
80 
(60 – 100) 
Gestation at delivery 
(weeks + days);  
Median (range) 
38+6 
(36+0 – 40+5) 
38+6 
(32+2 – 40+5) 
38+6 
(32+2 – 40+5) 
Preterm; N (%) 2 (10.00%) 2 (9.52%) 4 (9.76%) 
Birthweight <10
th
 centile 
(n) 
5 (25.00%) 4 (19.05%) 9 (21.95%) 
Pre-eclampsia; N (%) 0 1 (4.76%) 1 (2.44%) 
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Birth weight (BW) 
centile 
Median (range) 
35.06 
(1.06 – 94.29) 
28.87 
(4.09 – 96.66) 
29.97 
(1.06 – 96.66) 
Fetal demise in utero; N 
(%) 
0 0 0 
 
Table 1: Baseline clinical characteristics and demographics of study group (n=41). BMI, 
body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; BW, birth 
weight. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:  Flow diagram of trial participants.  
Declined to 
participate 
n = 14 
Recruited to study and 
randomised to treatment 
n = 44 
Withdrawn from study 
n = 1 
Premature rupture of membranes 
Eligible women approached 
n = 58 
  
Allocated to treatment 
n = 21 
Allocated to placebo    
n = 23 
Withdrawn from study 
n = 3 
Taste aversion at visit 1 (n =1) 
Developed pre-eclampsia at visit 2 (n=1) 
Termination of pregnancy after visit 2 (n=1) 
Analysed 
n = 20 
(n=21 for visits 1 & 2) 
Analysed 
n = 20 
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Of the 40 women who completed the full trial, 37/40 (92.5%) completed the acceptability 
questionnaire (see Supplementary Data File). 23/37 (62.2%) found it easy to take the 
beetroot juice daily; 1/37 (2.7%) found it difficult and 13/37 (35.1%) found it neither easy 
nor difficult. 20/37 (54.1%) women found it palatable. In terms of overall acceptability, 36/37 
(97.3%) said that if it was found to be beneficial, they would take it in the future. Both 
treatment interventions were well tolerated, and no adverse events were reported. 
 
The agreement of BP measurements between different modalities (clinic BP measured using 
the Alere Microlife monitors, arteriograph and NICOM measurements) is shown in Figure 2, 
and highlights the significant variability of BP measurements between modalities in pregnant 
women, particularly apparent for SBP. 
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Figure 2: Variation in heart rate and blood pressure across different measurement 
modalities.  Bland-Altman plots showing differences in heart rate (A & D), systolic blood 
pressure (B & E) and diastolic blood pressure (C & F) between measurement devices (Alere 
Microlife, NICOM and arteriograph monitors).  All measurements were performed with 
participant in the supine position. The average (mean) of both readings are shown on the x-
axis, with between-modality difference expressed on the y-axis. Dotted lines indicate 95% 
limits of agreement and line of bias as solid line (not visible where value approaches 0).  
BPM = beats per minute. 
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As shown in Table 2, there was no significant effect of nitrate supplementation compared 
with placebo on clinic BP at any time point across the study.   
  Nitrate Placebo  
 
Time 
(hours) 
Mean (SD) [C.I.] 
Delta 
(from 0h) 
Mean (SD) [C.I.] 
Delta     
(from 0h) 
P 
value 
Sitting 
SBP 
0 
133.90 (9.28) 
[129.56 – 138.24] 
 
132.45 (11.44) 
[127.25 – 137.66] 
 
 
 
3 
129.89 (9.40) 
[125.37 – 134.42] 
-3.74 (8.83) 
[-7.99 – 0.52] 
129.76 (9.99) 
[125.21 – 134.31] 
-2.69 (7.83) 
[-6.26 – 0.88] 
0.693 
24 
130.25 (10.70) 
[125.24 – 135.26] 
-3.65 (7.36) 
[-7.09 – -0.21] 
130.50 (9.10) 
[126.36 – 134.64] 
1.95 (11.23) 
[-7.06– 3.16] 
0.572 
168 
133.45 (9.83) 
[128.85 – 138.05] 
-0.45 (7.85) 
[-4.12 – 3.22] 
129.38 (9.55) 
[124.90 – 133.85] 
-3.65 (9.32) 
[-8.01– 0.71] 
0.247 
Sitting 
DBP 
0 
85.43 (6.07) 
[82.58 – 88.27] 
 
86.33 (7.48) 
[82.93 – 89.74] 
 
3 
83.03 (6.83) 
[79.73 – 86.32] 
-2.50  (4.33) 
[-4.59 –  -
0.41] 
82.83 (7.48) 
[79.06 – 86.61] 
-3.5 (8.48)    
[-7.36 – 0.36] 
0.647 
24 
83.08 (8.26) 
[79.21 – 86.94] 
-2.35 (7.02) 
[-5.63 – 0.93] 
85.07 (7.93) 
[81.46 – 88.68] 
-1.26 (7.27) 
[-4.57– 2.05] 
0.629 
168 
83.23 (7.17) 
[79.87 – 86.58] 
-2.20 (5.99) 
[-5.00– 0.60] 
85.43 (7.26) 
[82.03 – 88.82] 
-0.88 (6.71) 
[-4.01– 2.26] 
0.514 
 
Table 2: Dietary nitrate supplementation does not significantly reduce sitting BP compared 
with placebo. Data are presented as mean (±SD), [95% CIs). N=20-21 per group. 
 
 
Similarly, there was no significant different between nitrate and placebo groups on BP 
measured using any other modalities (arteriography, NICOM measurements; Supplementary 
Table 1).  Changes in vascular resistance/vessel stiffness and uteroplacental Doppler 
parameters were also comparable between dietary nitrate and placebo groups (summarised in 
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Supplementary Tables 2 and 3). Compliance amongst women for day 8 ABPM 
measurements was poor, with only 26/40 (65%) having daytime ABPM monitoring and 
19/40 (47.5%) completing the full 24 hours, and with an unequal split of treatment/placebo 
participants. As a result, insufficient data for statistical analysis were obtained using this 
modality of BP measurement. 
 
Following a single dose of dietary nitrate, both plasma nitrate and nitrite concentrations were 
significantly elevated at 3 hours post-ingestion compared with placebo levels (p<0.001 for 
both; Figure 3). At 24 hours after the initial dose, concentrations had returned to baseline 
values and after one week of daily supplementation, there were no significant differences in 
plasma nitrate or nitrite (day 8 measurements were taken prior to ingestion of the final 
treatment dose; Figure 3).  Salivary nitrate/nitrite concentrations across the intervention 
period showed similar responses, with significant elevations in both nitrate and nitrite at the 3 
hour time point (p<0.001 for both; Figure 3). However, in contrast to plasma concentrations, 
salivary nitrate concentrations were elevated on day 8 in the nitrate treatment arm, compared 
with placebo (p<0.01, Figure 3), reflecting a sustained effect of treatment in this biological 
compartment.  
 
The biochemical data highlighted significant variability in the assimilation and/or conversion 
of ingested nitrate to nitrite amongst the women in this study. In order to determine whether 
changes in BP were related to differences in treatment responses, pre-defined correlations 
were performed between the change in BP and change in plasma nitrite concentrations across 
the acute (0-3 hour) phase following treatment ingestion, where nitrite concentrations were 
maximal. These analyses revealed a significant correlation between the change in DBP and 
plasma nitrite across this timeframe, specifically in the dietary nitrate group (Figure 4). 
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Similar associations were seen between plasma nitrite and BP responses as measured using 
different modalities (arteriography, NICOM; Supplementary Figure 2), suggesting that a 
key determinant of BP responses to beetroot juice supplementation involves the assimilation 
and conversion of nitrate to nitrite. 
 
 
Figure 3:  Dietary nitrate elevates plasma and salivary nitrate and nitrite 
concentrations.  The effects of dietary nitrate (filled circles) or placebo (open circles) 
ingestion on (A) plasma nitrate, (B) plasma nitrite, (C) salivary nitrate and (D) salivary 
nitrite. Individual data points are shown, with mean ± SD indicated, and were analysed by 2-
way ANOVA followed by Sidak’s multiple comparisons test.  Significance shown between 
nitrate and placebo groups as **p<0.01 and ***p<0.001. N=17-21 per group. 
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Figure 4: Changes in plasma nitrite determine BP responses following acute nitrate 
ingestion.  Correlation of changes (∆) in plasma nitrite vs. changes in SBP (A&B) and DBP 
(C&D) in nitrate (filled circles, A&C) and placebo (open circles B&D) between 0-3 hour 
timepoints (i.e. following acute nitrate ingestion). BP measured using Alere microlife BP 
monitors. Data analysed using Pearson linear regression. N=17-21 per group. 
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4. Discussion: 
To our knowledge, this is the first trial to investigate the effects of dietary nitrate 
supplementation on blood pressure in pregnancy. In this study, we have confirmed 
acceptability and feasibility of beetroot juice supplementation in pregnancy, but we did not 
demonstrate a difference in blood pressure post treatment between the treatment and placebo 
groups (primary clinical outcome). However, despite considerable variability in BP 
measurements, in a pre-specified analysis we did identify significant correlations between 
changes in plasma nitrite concentrations and DBP responses following nitrate 
supplementation.  Previous studies in non-pregnant individuals have demonstrated that the 
peak change in plasma nitrite (and blood pressure) occurs between 2-4 hours after nitrate 
ingestion [22; 24; 27], corresponding with the time taken for enterosalivary nitrate-nitrite 
reduction [30]. We therefore targeted this time point for investigation in the present study, 
and demonstrated a similar, significant relationship between BP and plasma nitrite in 
pregnant women to that shown previously in non-pregnant populations [22]. Our data from 
this small feasibility trial therefore suggest that dietary nitrate may represent an effective 
intervention for the lowering of blood pressure in hypertensive pregnant women, but that the 
efficacy likely depends on the ability of the individual to assimilate and convert dietary 
nitrate to nitrite.  
 
There is a growing body of evidence illustrating the importance of oral bacteria in 
determining both normal, physiological blood pressure regulation [27], as well as in 
determining BP responses to dietary nitrate supplementation [31]. Elegant studies using 
antibacterial mouthwash to deplete the normal bacteria present in the oral cavity showed 
significantly reduced plasma and salivary nitrite levels; these changes were associated with a 
corresponding increase in BP, and ablation of oral nitrate reductase activity [27]. Smoking is 
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also associated with a significant reduction in oral nitrate reductase activity [32]. 
Interestingly, the one subject in the treatment arm of our study who was a smoker failed to 
show an increase in plasma nitrite levels at the 3 hour timepoint following nitrate ingestion; 
nitrite concentrations in fact were reduced over this timeframe, and BP in this subject 
increased. Whilst in our study this is one observation, data from other studies continue to 
highlight the important associations between oral bacterial populations and the nitrate-nitrite-
NO pathway in vivo. Although we have not directly investigated the role of oral bacterial 
nitrate reductase activity in this feasibility trial, our data suggest that this aspect will be 
critical to consider in future studies.  
 
Of note, in our study we observed a decline in BP across all women (i.e. in both the treatment 
and placebo arms of the study) across the initial 3-hour period.  This lowering of blood 
pressure by both nitrate-replete beetroot juice and a matched placebo control has been shown 
previously [31], although the authors did not address the finding directly. A recent meta-
analysis of clinical trials in which beetroot juice was used as the dietary intervention to 
deliver nitrate for lowering of blood pressure showed an attenuated effect size in studies 
utilising the placebo (nitrate-depleted beetroot juice control), as opposed to water or other 
control [33], suggesting nitrate-independent effects of beetroot juice on blood pressure 
reduction. In the present study, it could be that environmental factors (e.g. women 
acclimatising to the clinic environment, or being reassured of their baby’s wellbeing post-
ultrasound scan), may explain in part this response, in addition to potential effects of beetroot 
juice per se; any or all of these factors could lead to a physiological lowering of BP. It is also 
possible that the raised BMI of women in the treatment arm of the study could have 
attenuated the ability of nitrate to lower peripheral blood pressure, as has been shown 
recently in non-pregnant individuals [34].  
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The present study has also highlighted the significant variability associated with measuring 
BP in pregnant women in the clinical setting. Indeed, our measured standard deviation in the 
present dataset for SBP was ~9-10 mmHg, compared with the estimated 6.2 mmHg used in 
power calculations.  We attempted to gain a more holistic view of BP and cardiovascular 
changes across the intervention period by determining measurements of vessel 
stiffness/compliance (PWV) and vascular resistance (TPRI) in response to treatment.  
Comparing the different modalities, we found that the most reproducible measure in terms of 
BP was the standard, validated clinic BP monitor, and additionally found that SBP exhibited 
a higher degree of variability between modalities compared with DBP. Interestingly, a recent 
systematic review and meta-analysis carried out to assess the effects of dietary nitrate on BP 
found that the significant BP-lowering effect of nitrate was found only when resting clinic BP 
measures were used; non-significant differences were observed using 24-hour ABPM and 
home BP monitoring [35]. The information gained from this feasibility study will inform the 
design of future studies assessing BP responses to treatment interventions in pregnant 
women, a challenging group in which to run well-controlled clinical trials. 
 
The strengths of this study are its randomised double-blind controlled design and a high level 
of compliance in taking the daily dietary intervention (all women reported successfully 
completing the 8-day treatment period). In terms of limitations, our BP data indicated a 
higher degree of variability than predicted, thus this feasibility trial has highlighted 
methodological issues with obtaining reproducible BP measurements in pregnant women. 
Future trials will need to ensure that multiple BP measurements are taken, ideally following 
ultrasound scan reassurance of fetal well-being and a defined acclimatisation period, in order 
to reduce variability. We were also unable to obtain ABPM measurements from a significant 
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proportion of participants, as women were unable to tolerate this intervention.  The main 
reason cited was the disturbed sleep as a result of these measurements being taken every hour 
during the overnight period. In addition, we did not strictly control the diets of the 
participants during the supplementation period, which will likely have contributed to the 
variability seen in terms of plasma nitrate/nitrite concentrations, as well as influencing the BP 
and other cardiovascular variables measured but again dietary restrictions or enforced fasting 
periods can pose issues in pregnant women. These factors, combined with a relatively diverse 
population (in terms of ethnicity, body mass index and baseline BP), are likely to have 
contributed to the degree of variability seen in salivary and plasma nitrate/nitrite levels, as 
well as in the response to treatment. Despite these limitations, our data suggest that dietary 
nitrate may be a promising therapeutic intervention for use in pregnancy amongst women 
who are able to utilise it. 
 
Given the paucity of treatment options for hypertensive pregnant women, the development of 
new interventions that improve BP regulation and lead to sustained BP lowering represent an 
ongoing unmet need. If efficacious, dietary approaches are more likely to deliver realistic 
interventions, given issues of compliance and risk that surround pharmacological treatment of 
pregnant women. Importantly, the current study has identified that dietary nitrate 
supplementation, via beetroot juice, is well tolerated and acceptable to pregnant women. A 
recent review has highlighted the need for further preclinical and clinical studies to address 
the safety of dietary nitrate supplementation [36].  Our ongoing preclinical studies and 
planned future clinical trials are addressing this knowledge gap; however, the results of this 
feasibility trial have shown that ingestion of 400mg of nitrate for 8 days after 22 weeks 
gestation is safe and acceptable for both mother and baby. 
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Our data suggest that the ability to convert nitrate to nitrite determines the BP-lowering 
efficacy of dietary nitrate supplementation. Further studies are required to confirm this 
finding, and to investigate the potential for manipulation of bacterial populations (e.g. 
concurrent probiotic supplementation) that would promote the utilisation of dietary nitrate, its 
conversion to nitrite, and ultimately enhance the BP lowering effects of this dietary 
intervention. 
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